COVALENT FLT3 INHIBITOR BMF-500 IN RELAPSED OR REFRACTORY (R/R) ACUTE LEUKEMIA (AL): PRELIMINARY PHASE 1 DATA FROM THE COVALENT-103 STUDY (NCT05918692)

hydroxyurea - Generic mfg.

Venclexta (venetoclax) - Roche, AbbVie

Xospata (gilteritinib) - Astellas

BMF-500 - Biomea Fusion

https://library.ehaweb.org/eha/2025/eha2025-congress/4160595/farhad.ravandi-kashani.covalent.flt3.inhibitor.bmf-500.in.relapsed.or.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2882%2Aot_id%3D31560%2Amarker%3D5844%2Afeatured%3D19595

Farhad Ravandi-Kashani; Yasmin Abaza; Taha Aljuhaishi; Cecilia Arana Yi; Martha L Arellano; Talha Badar; Kebede Benga; Mitul D. Gandhi; Bradley Christensen; Brian A. Jonas; Jonathan Kolitz; Paul Koller; Richard Larson; Ioannis Mantzaris; James McCloskey; Ayman H. Qasrawi; Marcello Rotta; Gary Schiller; Bart Scott; Catherine Smith; Uzma Ahmed; Elizabeth Chong; Weiqun Li; Stephan Morris; Mona Vimal; Ganesh Waghmare; Thomas Butler; Eunice Wang

May 16, 2025